Of the 6787 patients analyzed, 5805 (85.5%) were prescribed SGLT-2 inhibitors for DM, 550 (8.1%) for CKD, and 432 (6.4%) for HF. This evidence concerns the gene SLC5A2 and chronic kidney disease.